CLINICAL EXPERIENCE WITH CEFOXITIN (CFX) IN COMPLICATED URINARY TRACT INFECTION

Cefoxitin (CFX) was intravenously administered to 106 patients with complicated urinary tract infection at a daily dose of 2-4 g for 5 days. The results were summarized as follows; 1. As to the overall clinical efficacy, excellent, response was seen in 25%, moderate in 32% and poor in 43%. 2. Pyuria was cleared in 33, decreased in 14, and unchanged in 53 cases. 3. Bacteriuria was eliminated in 51, decreased in 2, replaced in 18, and unchanged in 29 cases. 4. As to the bacteriological response to CFX, 94 (71 %) were eradicated, and 39 (29%) persisted out of 133 strains isolated. 5. Side effects were observed in 4 of 106 cases. Subjective side effects were not observed, but one case of mild pharyngeal edema and 3 cases of transient elevation of transaminase. From the above results, CFX would be a useful drug in the treatment of complicated urinary tract infections